CHMP recommend market authorisation for belantamab mafodotin (Blenrep)

This humanised IgG1κ monoclonal antibody and cytotoxic agent combination is intended to be licensed as monotherapy for multiple myeloma in adults, who have had four prior therapies including a proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.

European Medicines Agency